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Abstract Stress urinary incontinence (SUI) is highly
prevalent. As of now, there is no minimally invasive long-
term treatment available. Adult stem cells are nonimmuno-
genic and have the ability to self-renew and to differentiate
into multiple cell types. Over the past decade, in vivo
studies have described periurethral injections of adult-
derived stem cells for the treatment of SUI. The ultimate
goal has been to achieve a permanent cure for SUI by
restoration of the intrinsic and extrinsic urethral sphincter
and the surrounding connective tissue, including peripheral
nerves and blood vessels. For this purpose, future studies
need to focus on delivery systems, cell survival, and
functional improvement of the urethral closure mechanism,
including improvement of innervation and vascularization.
Keywords Stress urinary incontinence.Adult stem cell
therapy.Mesenchymal-derived stem cells.Adipose-derived
stem cells.Bone marrow-derived stem cells.
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Introduction
Urinary incontinence affects about 17 million people in
the United States with an estimated annual cost of $32
billion [1]. Stress urinary incontinence (SUI), a common
form of urinary incontinence, also is highly prevalent,
especially in women [2]. SUI is associated with significant
impairment in quality of life and has a significant
socioeconomic impact, with costs steadily increasing as
the population ages [3]. The female urethra consists of a
proximal, a midurethral, and a distal segment. The elongation
of detrusor muscle fibers at the bladder neck characterizes the
proximal urethral segment. The midurethra consists of the
inner smooth and outer striated muscles, which mainly build
the urethral sphincteric complex [4]. The smooth muscle
consists of a longitudinal and circumferential layer and
is encircled by the striated rhabdosphincter muscle.
Urinary continence depends on the integrity of the
intrinsic sphincter and the extrinsic sphincter. The
intrinsic sphincter consists of the mucosa, the submu-
cosa, an estrogen-dependent vascular plexus, and
smooth muscle layers. It achieves urethral coaptation
passively and involuntarily. The extrinsic sphincter
consists of the striated urethral rhabdosphincter and
compresses the urethra voluntarily supported by the
compressor urethrae muscle, the pubococcygeus, and the
urethrovaginal sphincter muscle [4]. The pathophysiolo-
gy of SUI is multifactorial, including atrophy of the
smooth muscle and the rhabdosphincter, changes in
connective tissue, changes in blood perfusion of the
periurethral vasculature and submucosal tissue, and loss
of neuronal mass. Those changes are seen after vaginal
delivery [5] and as part of the aging process [6], which
contributes to the development of this condition.
A number of surgical procedures are available to treat
SUI. Injectable bulking agents are minimally invasive but
have poor long-term efficacy. More invasive approaches,
such as sling procedures and bladder neck suspensions, are
more efficacious, but have a higher morbidity [7]. These
limitations have motivated investigations into therapies that
may provide safer and longer-lasting outcomes in the
treatment of SUI by repairing the damaged continence
mechanism. Given stem cells’ ability to induce tissue
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cells for the treatment of SUI. Stem cells represent a self-
renewing population of cells derived from healthy tissue
that can be differentiated into a variety of cells. The
ideal strategy for curing SUI would allow for the
regeneration of functional periurethral tissue to provide
adequate mucosal coaptation and to restore resting
urethral closure pressures.
Multiple animal models have been used to study the
effect of stem cells in tissue regeneration of the urethra. A
number of experimental models that simulate some of the
components of the human pathophysiology of SUI due to
trauma of vaginal delivery, such as vaginal balloon dilation
[8] and pudendal crush injuries [9], have been described.
Other more durable models, such as pudendal or spinal cord
transsection [10, 11] and urethrolysis [12], also have been
validated.
Use of Adult Stem Cells for Restoration of the Urethral
Sphincteric Mechanism
Embryonic stem cells are pluripotent cells obtained from
the inner cell cluster of blastocytes. They have the
potential to differentiate in vitro into cells from all three
embryonic germ layers. To avoid ethical and political
considerations limiting the use of embryonic stem cells,
research into therapies for SUI has focused on the use
of autologous adult-derived stem cells. These are a self-
regenerating population of cells, are present in niches in
multiple organs, and hold the plasticity to transdifferen-
tiate into cell types from different germ layers. In
contrast to embryonic stem cells, adult stem cells tend
not to be immortal and have more limited differentiation
potential. These limitations also may make them safer,
because they do not tend to form teratomas.
Investigations of the use of stem cells for the
treatment of SUI have focused on mesenchymal-
derived stem cells. Mesenchyme is connective tissue
derived from the embryonic mesoderm. Many of these
cells are easily expanded in vitro, can differentiate into
cells derived from mesoderm as well as other germ
layers, and are capable of releasing paracrine factors to
stimulate the regeneration of surrounding tissue [13].
These cells can be isolated from different adult tissue
sources, such as adipose tissue, liver tissue, muscle,
amniotic fluid, placenta, umbilical cord, dental pulp, and
bone marrow [14], and share similar surface immunophe-
notype and multilineage differentiation capacity [15].
Multiple adult-derived stem cells have been studied for
the treatment of SUI. Table 1 provides a chronological
overview of the literature of animal and human studies
that have been conducted since the year 2000.
Preclinical Animal Studies
Bone Marrow-Derived Stem Cells
Of all mesenchymal stem cells, bone marrow-derived stem
cells (BMSCs) have been most widely studied. They have
been used for the regeneration of cardiac muscle [16],
bladder detrusor muscle [17], anal sphincter muscle [18],
and many other structures [19]. In a pilot study, Drost et al.
[20] transplanted BMSCs into the bladder neck of athymic
rats and pretreated them with the differentiation agent 5-
azacitidine to induce myogenic differentiation. BMSCs
expressed smooth and striated muscle antigens. Autologous
BMSCs also have been transplanted into injured urethral
sphincters of Sprague-Dawley rats [21￿]. Urethral sphinc-
ters were injured with urethrolysis and cardiotoxin injec-
tion. One week after the urethral injury, the cultured
BMSCs were injected periurethrally. Abdominal leak point
pressure (ALPP) was measured preoperatively and 13 weeks
after cell injection. Histological and immunohistochemistry
evaluation verified that transplanted BMSCs survived and
differentiated into striated muscle cells and peripheral nerve
cells to a significantly greater degree than the cell-free
group. Nevertheless, no significant difference was seen in
ALPP among the groups [21￿].
Muscle-Derived Stem Cells
Postnatal regeneration of skeletal muscle has been
thought to emerge from local progenitors, such as
skeletal muscle satellite cells. Muscle-derived progenitor
or stem cells (MDSCs) can naturally differentiate to
multinucleated muscle fibers and display stem cell
characteristics [22]. MDSCs have the ability to undergo
long-term proliferation, multipotent differentiation, and
self-renewal. MDSCs are quiescent satellite cells found
in myofibers that can proliferate to form myoblasts and,
eventually, form myotubes and new muscle tissue.
Chancellor et al. [23] conducted the first experiments
u s i n gM D S C sh a r v e s t e df r o ms triated muscle. In vitro
expanded skeletal myoblasts obtained from mice were
injected into the urinary tract of Sprague-Dawley rats.
Contractile myoblasts and myotubes were verified by
positive desmin expression [23]. Longer survival times
of up to 28 days for autologous MDSCs transplanted
into the bladder and urethral wall of rats have been
demonstrated by Yokoyama et al. [24] and Yiou et al.
[25]. Studies have shown that MDSCs are capable of
restoring muscular contraction of the urethral sphincter
2 weeks after injection [26] and contribute to the
functional recovery of damaged pelvic nerves [27]. It
has been suggested that the formation of myotubes may
activate intrinsic nerve regeneration and formation of
42 Curr Urol Rep (2011) 12:41–46neuromuscular junctions [28]. The potential to reconsti-
tute peripheral nerves also has been seen after transplan-
tation into severely damaged skeletal muscle [29]. The
same group has shown that MDSCs contribute to the
synchronized reconstitution of blood vessels, muscle
fibers, and peripheral nerves [29].
In animal models, MDSCs also may improve neurogenic
bladder dysfunction by reconstitution of damaged peripheral
Table 1 Chronological overview of in vivo adult stem cell injection for treatment of urinary incontinence over the last decade
Study Stem cell
source
Delivery
vehicle
Species (n) Target
organ(s)
Model of
incontinence
Cell tracking Follow-up
time
Chancellor et al. [23] MDSC None Female SD
rats (8)
Urethra,
bladder
None Adenoviral vector 3–4 days
Yokoyama et al. [24] MDSC None Female SD
rats (6)
Urethra,
bladder
None Retroviral vector 28 days
Huard et al. [50] MDSC None SCID mice,
female SD rats
Bladder None Adenoviral vector 6 months
Yiou et al. [51] MDSC None Male swiss
mice (25)
Urethra Sphincteric injection
of noxetin
Fluorescent
labeling
1 month
Lee et al. [52] MDSC None Female SD
rats (34)
Urethra Sciatic nerve
denervation
None 4 weeks
Cannon et al. [26] MDSC None Female SD
rats (18)
Urethra Sciatic nerve
denervation
None 2 weeks
Lee et al. [53] MDSC Collagen Female SD
rats (40)
Urethra Pudendal nerve
transection
None 12 weeks
Peyromaure et al. [54] MDSC None Female Wistar
rats (24)
Urethra None Retroviral vector 0–90 days
Chermansky et al. [55] MDSC None Female SD rats
(25)
Urethra Urethral
electrocauterization
Retroviral vector 6 weeks
Kanematsu et al. [17] BMSC Acellular
matrix
Female SD rats
(21)
Bladder N/A Fluorescent
labeling
12 weeks
Jack et al. [40] ADSC None Athymic rats
(8); SCID mice
(6)
Urethra,
bladder
None Fluorescent
labeling
12 weeks
Kwon et al. [56] MDSC,
fibroblasts
None Female SD
rats (30)
Urethra Sciatic nerve
denervation
None 4 weeks
Zeng et al. [42] ADSC PLGA-ms Female athymic
rats (88)
Urethra Urethrolysis None 12 weeks
Mitterberger et al. [31] MDSC,
fibroblasts
None Pigs (5) Urethra None Fluorescent
labeling
3 weeks
Strasser et al. [43]
a MDSC,
fibroblasts
Collagen Men (21);
women (42)
Urethra SUI None 12 weeks
Strasser et al. [44]
a MDSC,
fibroblasts
Collagen Women (42) Urethra SUI None 12 months
Kleinert and Horton
[45]
MDSC,
fibroblasts
Collagen Women (42) Urethra SUI None 12 months
Carr et al. [46￿￿] MDSC None Women (8) Urethra SUI None 12 months
Mitterberger et al. [57] MDSC,
fibroblasts
None Men (63) Urethra PPI None 12 months
Hoshi et al. [28] MDSC None Male SD rats,
athymic rats
Urethra Nerve bundle
transection
GFP transfection 12 weeks
Drost et al. [20] BMSC None Athymic rats Bladder None Fluorescent
labeling
8 days
Fu et al. [35] ADSC None Female SD
rats (20)
Urethra,
bladder
Vaginal balloon
dilation
None 3 months
Kinebuchi et al. [21￿] BMSC None Female SD
rats (25)
Urethra Urethrolysis GFP transfection 13 weeks
Nitta et al. [30￿￿] MDSC None Female
athymic rats
Bladder neck Transection of
pelvic plexus
bladder branch
GFP transfection 4 weeks
Yamamoto et al. [58] ADSC None Men (2) Urethra PPI None 6 months
Herschorn et al. [47] MDSC None Women (29) Urethra SUI None 12 months
Lin et al. [41] ADSC None Female SD
rats (28)
Urethra Vaginal balloon
dilation
Fluorescent
labeling
4 weeks
aStudy retracted.
ADSC adipose-derived stem cells; BMSC bone marrow-derived stem cells; GFP green fluorescent protein; MDSC muscular-derived stem cells; N/
A not available; PPI postprostatectomy incontinence; PLGA-ms poly-lactic-glycolic acid microspheres; SCID severe combined immunodeficien-
cy; SD rats Sprague-Dawley rat; SUI stress urinary incontinence.
Curr Urol Rep (2011) 12:41–46 43nerve cells (eg, Schwann cells, perineum) and vascular cells
(eg, vascularsmoothmusclecells,pericytes,endothelial cells)
[30￿￿]. Preclinical trials for the application of this technology
also have been conducted in larger animals. Myoblasts have
been used for the treatment of SUI in a pig model and
injected to the striated urinary sphincter. The animals have
shown an increase in urethral pressure profile and muscular
myofibrils [31].
Adipose-Derived Stem Cells
Fat tissue contains pluripotent cells, termed as adipose-
derived stem cells (ADSCs), which have the ability to
differentiate into cells of the same and of another germ
layer, such as adipogenic, chondrogenic, myogenic, osteo-
genic, and neurogenic cells [32]. For the treatment of
urinary incontinence, ADSCs are of special interest for
mesodermal and neuronal regeneration and to promote
revascularization. ADSCs are easily obtained from mini-
mally invasive liposuction [33]. ADSCs can differentiate
into fibroblasts [34], myoblasts [35], smooth muscle cells
[36], endothelial cells [37], or skeletal muscle [38]. They
can express specific striated muscle markers (eg, desmin,
myod1, myogenin, myosin heavy chain), form multinucle-
ated cells characteristic of myotubules, and have been
shown to regenerate the functional capacity of damaged
skeletal muscle [38]. ADSCs express nerve growth factor at
the time of neural differentiation. Neural-differentiated
ADSCs present glial characteristics and promote nerve
regeneration, as observed 7 days after transplantation in a
rat model in vivo [39]. Rodríguez et al. [36] have described
conditions necessary to differentiate ADSCs into functional
smooth muscle cells, which express early and late smooth
muscle markers, such as α-smooth muscle actin, caldes-
mon, SM22, smoothelin, and myosin heavy chain. Smooth-
muscle differentiated ADSCs have the ability in vitro to
contract and relax in response to pharmacologic stimuli
[36]. In an immune-competent, incontinent rat model of
SUI, periurethrally injected ADSCs exhibited in vivo
differentiation into smooth muscle cells and improved
urethral resistance [40]. Fu et al. [35] predifferentiated
ADSCs with 5-azacitidine into myoblasts and injected these
cells periurethrally into incontinent rats. After 3 months, a
significant difference in bladder capacity and leak point
pressure was observed between the control group and the
pretreated group. An increased number of myoblasts under
the mucosa and α-smooth muscle actin expression was
observed 3 months after implantation [35]. Human ADSCs
also have been delivered periurethrally in an athymic rat
model [41]. ADSCs, which expressed smooth muscle
markers, were viable in the lower urinary tract for up to
12 weeks. Other studies demonstrated improved urethral
function after periurethral injection of ADSCs [42].
Human Studies
Few human trials have been conducted using autologous
derived stem cells in the treatment of urinary incontinence,
which all involved the use of MDSCs. Strasser et al. [43,
44] conducted the first clinical experiments in women and
men with SUI. Myoblasts and fibroblasts were obtained
from muscular biopsies of each patient. Autologous
myoblasts were injected under transurethral ultrasound
guidance into the rhabdosphincter of the midurethra.
Separate injections of a suspension of autologous fibro-
blasts and collagen, which functioned as carrier material,
were additionally performed into the submucosa cranial and
caudal to the injection side of the myoblasts with good
outcomes at 1 year [44]. Unfortunately, these published
study results have been retracted due to deficiencies in
obtaining patients’ consents, protocol irregularities, and a
missing ethical committee approval [45]. Carr et al. [46]
presented therapeutic efficacy in a clinical trial after
transurethral injection of autologous MDSCs in eight
women diagnosed with SUI. The study end point was at
12 months. Five out of eight women reported improvement,
as demonstrated by a voiding diary and pad weight test,
with the onset between 3 to 8 months postinjection. One
patient achieved complete continence up to the study end
point at 12 months. Two patients achieved reduction of
50% from their baseline incontinence episodes and received
a reinjection after their initial injection between 4 and
8 months later with minor improvement [46]. The same
group demonstrated a treatment effect of SUI in a blinded
randomized study enrolling 29 female patients with SUI. In
this study, patients received cystoscopic-assisted transure-
thral injections of autologous MDCSs at different cell
concentrations with a second injection after 3 months. The
follow-up end point was 1 year. Almost half of the patient
population, who received two injections, reported no
leakage at 12 months [47]. These promising early clinical
results warrant further evaluation to validate results,
determine durability and focus on safety and possible
adverse reactions.
Conclusions
Future Directions
Although promising preclinical and clinical studies have
demonstrated the potential for the use of adult-derived stem
cells in the treatment of SUI, a lot is yet to be known. We
have little understanding of how these cells are mediating
their effects on the continence mechanism, how long they
survive, or if they induce other local mediators, which may
improve continence. There also are concerns regarding the
44 Curr Urol Rep (2011) 12:41–46tendency for stem cells to migrate to other organs [48, 49].
Studies need to be conducted to increase the survival and
retentionofthesecellsinthetargettissues.Futurestudiesneed
toevaluate not onlythe mechanism ofactionofthese cells but
alsothelong-termsafety.Lastly,myogenicdefectsarejustone
of the multiple components likely leading to SUI. Little has
been done to evaluate how regeneration of neuronal mass or
vascular components may contribute to the treatment of SUI
and regeneration of functional urethral tissue.
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